Pfizer-Hospira Injectables Plant in India Hit With Further FDA Scrutiny, an Industrial Info Market Brief

U.S. pharmaceutical giant Pfizer Incorporated has again halted production at its beleaguered aseptic injectables plant in South India after the U.S. Federal Drug Administration slammed the facility with 11 Form-483 observations. More than three years after Pfizer paid roughly $17 billion to acquire the Hospira Healthcare India facility in Tamil Nadu, the drug maker continues to encounter quality-control issues. The plant also received citations in 2015 and a warning letter in 2013. Industrial Info is tracking 723 pharmaceutical formulation plants in India with more than 2,100 functional management contacts.